Androgen receptor expression in a Sri Lankan patient cohort with early breast carcinoma

Wijesinghe, Harshima Disvini; Wijesinghe, Gayani Kokila; Mansoor, Zahara; Vigneshwara, Sanjeev; Fernando, Janakie; Gunasekera, Dehan; Lokuhetty, Menaka Dilani Samarawickrama

doi:10.1186/s12905-020-01068-5

BMC Women's Health

Table 4 Association of pathological parameters and AR expression

From: Androgen receptor expression in a Sri Lankan patient cohort with early breast carcinoma

Pathological Parameter		AR expression		p-value (Chi - square)
Pathological Parameter		Positive	Negative	p-value (Chi - square)
Histological type	Ductal	49^a (86.0%)	76^a (90.5%)	0.657
	Lobular	3^a (5.3%)	3^a (3.6%)
	Mucinous	2^a (3.5%)	1^a (1.2%)
	Micropapillary	0^a (0%)	1^a (1.2%)
	Metaplastic	2^a (3.5%)	2^a (2.4%)
	Adenoid cystic carcinoma	0^a (0%)	1^a (1.2%)
	Carcinoma with neuroendocrine features	1^a (1.8%)	0^a (0%)
T stage	T1	11^a (19.3%)	13^a (15.5%)	0.593
	T2	41^a (71.9%)	65^a (77.4%)
	T3	5^a (8.8%)	6^a (7.1%)
N stage	N0	27^a (55.1%)	45^a (57.0%)	0.452
	N1	11^a (22.4%)	15^a (19.0%)
	N2	7^a (14.3%)	7^a (8.9%)
	N3	4^a (8.2%)	12^a (15.2%)
TNM stage	Stage 1	8^a (14.0%)	9^a (10.7%)	0.797
	Stage 11	36^a (63.2%)	57^a (67.9%)
	Stage 111	13^a (22.8%)	18^a (21.4%)
Histological Grade	Grade 1	15^a (26.3%)	16^a (19.0%)	0.497
	Grade 2	21^a (36.8%)	30^a (35.7%)
	Grade 3	21^a (36.8%)	38^a (45.2%)
Ductal carcinoma in situ	Absent	21^a (36.8%)	52^b (61.9%)	0.003*
Ductal carcinoma in situ	Present	36^a (63.2%)	32^b (38.1%)	0.003*
Necrosis	Absent	38^a (66.7%)	48^a (57.1%)	0.031*
	Focal	15^a (26.3%)	16^a (19.0%)
	Moderate-extensive	4^a (7.0%)	20^b (23.8%)
Tumour margin	Pushing	43^a (75.4%)	64^a (76.2%)	0.918
Tumour margin	Infiltrative	14^a (24.6%)	20^a (23.8%)	0.918
Lympho vascular invasion	Absent	48^a (84.2%)	76^a (90.5%)	0.262
Lympho vascular invasion	Present	9^a (15.8%)	8^a (9.5%)	0.262
Central desmoplasia/Hyalinization	Absent to mild	24^a (42.1%)	40^a (47.6%)	0.519
Central desmoplasia/Hyalinization	Moderate-extensive	33^a (57.9%)	44^a (52.4%)	0.519
Desmoplasia/hyalinisation at edge	Absent to mild	43^a (75.4%)	68^a (81.0%)	0.432
	Moderate to extensive	14^a (24.6%)	16^a (19.0%)	0.432
Lymphoid infiltrate in centre	Absent to mild	49^a (86.0%)	66^a (78.6%)	0.267
	Moderate to extensive	8^a (14.0%)	18^a (21.4%)	0.267
Lymphoid infiltrate at edge	Absent to mild	46^a (80.7%)	53^b (63.1%)	0.025*
Lymphoid infiltrate at edge	Moderate to extensive	11^a (19.3%)	31^b (36.9%)	0.025*
Vascular density at edge	< 5 vessels/mpf	16^a (28.1%)	21^a (25.0%)	0.684
Vascular density at edge	≥5 vessels/mpf	41^a (71.9%)	63^a (75.0%)	0.684
Calcification	Absent	52^a (91.2%)	79^a (94.0%)	0.522
Calcification	Present	5^a (8.8%)	5^a (6.0%)	0.522
Cell margins	Distinct	26^a (45.6%)	42^a (50.0%)	0.609
Cell margins	Indistinct	31^a (54.4%)	42^a (50.0%)	0.609
ER status	Positive	36^a (66.7%)	32^b (38.1%)	0.001*
ER status	Negative	18^a (33.3%)	52^b (61.9%)	0.001*
PR status	Positive	40^a (70.2%)	35^b (42.2%)	0.001*
PR status	Negative	17^a (29.8%)	48^b (57.8%)	0.001*
HER2 status	Positive	7a (12.3%)	13a (15.5%	0.594
HER2 status	Negative	50a (87.7%)	71a (84.5%)	0.594
Treatment	Hormonal treatment	27^a (75.0%)	23^b (47.9%)	0.012*
	Chemotherapy	7^a (19.4%)	25^b (55.6%)	0.001*
	Anti HER2 therapy	2a (5.7%)	8a 17.4%)	0.114

*Statistically significant ^a,b Each superscript letter denotes a subtype whose column proportions do not differ significantly from each other at the 0.05 level
hpf – High power field (× 40 objective, field diameter 0.05 mm)
mpf – Medium power field (× 10 objective, field diameter 0.2 mm)
Percentages have been calculated to represent the prevalence of each clinical feature within each category of AR status

Back to article page

ISSN: 1472-6874

Contact us

Submission enquiries: bmcwomenshealth@biomedcentral.com
General enquiries: ORSupport@springernature.com